Explore

Capbase

Immuno Cancer Biotherapeutics, Inc. — Funding, Investors & Profile — Capbase

Private

Private securities offering disclosed via SEC Form D.

Biotechnology

$75KSource: [SEC]Raised (recorded)

UndisclosedSource: [SEC]Last valuation

Immuno Cancer Biotherapeutics, Inc. filed a Form D notice of exempt offering with the SEC.

1 round

1 round recorded · latest Private placement (Form D), Oct 2026 · $75K recorded

No investors recorded yet for Immuno Cancer Biotherapeutics, Inc..

Leadership

James RoblExecutive OfficerSince 2026Source: [SEC]

Immuno Cancer Biotherapeutics, Inc. has no recorded acquisitions.

Still private — no exit on record.

No diversity signals recorded yet for Immuno Cancer Biotherapeutics, Inc..

Data aggregated from SEC EDGAR, Wikidata, and community contributions. Spotted an error? Propose a change or report an issue. Work at Immuno Cancer Biotherapeutics, Inc.? This is my company.

Seed

Sector

Healthcare